Literature DB >> 24966957

Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.

Zhen Ning1, Aman Wang2, Jinxiao Liang1, Jiwei Liu2, Tao Zhou2, Qiu Yan3, Zhongyu Wang1.   

Abstract

Nek2 is a serine/threonine kinase that has a critical role in mitosis during the cell division process. Despite its importance in centrosome regulation and spindle formation, no direct binders are reported between human pancreatic cancer and Nek2 protein. Our aim in studying Nek2 expression and survival in PDA patients is to determine whether Nek2 is a valuable prognostic factor in PDA tumorigenesis. We found that Nek2 mRNA was elevated in PDA tissues. A high level of expression of Nek2 was significantly correlated with histological differentiation (P=0.042), lymph node metastasis (P=0.003) and tumor stage (P=0.001). Patients with a high Nek2 expression had a significantly worse overall survival (OS) than those patients with low Nek2 expression (P=0.002). Univariate and multivariate analysis revealed that high expression of Nek2 could serve as an independent predictor of poor prognosis. These results indicate that Nek2 could be a promising prognostic molecular marker and an attractive therapeutic target for PDA.

Entities:  

Keywords:  Nek2; pancreatic ductal adenocarcinoma; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24966957      PMCID: PMC4069945     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  32 in total

1.  Inhibition of centrosome separation after DNA damage: a role for Nek2.

Authors:  Lynda Fletcher; George J Cerniglia; Erich A Nigg; Tim J Yend; Ruth J Muschel
Journal:  Radiat Res       Date:  2004-08       Impact factor: 2.841

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators.

Authors:  A M Fry; P Meraldi; E A Nigg
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

5.  The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.

Authors:  Daniel G Hayward; Robert B Clarke; Alison J Faragher; Meenu R Pillai; Iain M Hagan; Andrew M Fry
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Authors:  Wen Zhou; Ye Yang; Jiliang Xia; He Wang; Mohamed E Salama; Wei Xiong; Hongwei Xu; Shashirekha Shetty; Tiehua Chen; Zhaoyang Zeng; Lei Shi; Maurizio Zangari; Rodney Miles; David Bearss; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Cell       Date:  2013-01-14       Impact factor: 31.743

7.  Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.

Authors:  Yusuke Takahashi; Takeshi Iwaya; Genta Sawada; Junji Kurashige; Tae Matsumura; Ryutaro Uchi; Hiroki Ueo; Yuki Takano; Hidetoshi Eguchi; Tomoya Sudo; Keishi Sugimachi; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori; Koshi Mimori
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

Review 8.  Never say never. The NIMA-related protein kinases in mitotic control.

Authors:  Matthew J O'Connell; Michael J E Krien; Tony Hunter
Journal:  Trends Cell Biol       Date:  2003-05       Impact factor: 20.808

9.  Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.

Authors:  Jaehyung Lee; Lauren Gollahon
Journal:  Int J Oncol       Date:  2013-01-22       Impact factor: 5.650

10.  Analysis of the cellular centrosome in fine-needle aspirations of the breast.

Authors:  Hui-qin Guo; Meixia Gao; Jinfang Ma; Ting Xiao; Lin-lin Zhao; Yanning Gao; Qin-jing Pan
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  25 in total

Review 1.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma.

Authors:  Huajie Liu; Bin Liu; Xianzeng Hou; Bo Pang; Pengbo Guo; Wanli Jiang; Qian Ding; Rui Zhang; Tao Xin; Hua Guo; Shangchen Xu; Qi Pang
Journal:  J Neurooncol       Date:  2017-03-21       Impact factor: 4.130

3.  Effect of silencing NEK2 on biological behaviors of HepG2 in human hepatoma cells and MAPK signal pathway.

Authors:  Mei-Xia Zhang; Xi-Ming Xu; Peng Zhang; Na-Na Han; Jun-Jian Deng; Ting-Ting Yu; Yuan-Yuan Gan; Xiao-Qin He; Zhi-Xiong Long
Journal:  Tumour Biol       Date:  2015-09-03

Review 4.  Role of NEK2A in human cancer and its therapeutic potentials.

Authors:  Jiliang Xia; Reinaldo Franqui Machin; Zhimin Gu; Fenghuang Zhan
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

5.  Molecular modeling and docking of small molecule inhibitors against NEK2.

Authors:  Balaji Ramachandran; Sabitha Kesavan; Thangarajan Rajkumar
Journal:  Bioinformation       Date:  2016-04-10

6.  Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer.

Authors:  Yuan-Xiang Shi; Ji-Ye Yin; Yao Shen; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

7.  Transcriptional landscape of human cancers.

Authors:  Mengyuan Li; Qingrong Sun; Xiaosheng Wang
Journal:  Oncotarget       Date:  2017-05-23

8.  NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.

Authors:  Gang Li; Yanping Zhong; Qingrong Shen; Yi Zhou; Xiaofang Deng; Cuiping Li; Jiagui Chen; Ying Zhou; Min He
Journal:  Int J Oncol       Date:  2017-01-03       Impact factor: 5.650

9.  MiR-486-5p negatively regulates oncogenic NEK2 in hepatocellular carcinoma.

Authors:  Shun-Jun Fu; Jian Chen; Fei Ji; Wei-Qiang Ju; Qiang Zhao; Mao-Gen Chen; Zhi-Yong Guo; Lin-Wei Wu; Yi Ma; Dong-Ping Wang; Xiao-Feng Zhu; Xiao-Shun He
Journal:  Oncotarget       Date:  2017-05-05

10.  NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition.

Authors:  Yi Zhang; Wei Wang; Yifei Wang; Xiaohui Huang; Zhaohui Zhang; Bin Chen; Wenxuan Xie; Shaoqiang Li; Shunli Shen; Baogang Peng
Journal:  Oncol Rep       Date:  2018-01-22       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.